Macular Degeneration Trial, Recruiting NCT04129021 Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT04129021
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have an eye condition, or healthy volunteers with no eye condition
  • People who have signed a consent form to participate
  • People who are covered by health insurance

Who may not be able to join:

  • People who have a history of being sensitive to light (photosensitivity)
  • People who have recently received a type of light-based treatment called photodynamic therapy (confirm with trial site for timing details)
  • People who are currently taking medications that list light sensitivity as a side effect
  • People who have a pacemaker or any other electronic medical device implanted in their body
  • People who currently have a viral eye infection or any other active infectious disease
  • People who have skin sores or wounds on their neck or forehead
  • People who may be at higher risk of eye damage from light exposure, such as those missing the natural lens of the eye, or those with reduced light sensitivity due to a disease at the back of the eye
  • Women who are pregnant or currently breastfeeding
  • People who would not be able to attend all required appointments throughout the full study period
  • People considered to be vulnerable (confirm with trial site for specific definition)
  • People whose eye anatomy puts them at risk of a condition where the drainage angle inside the eye could close (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michel PAQUES, Centre Hospitalier National d'Ophtalmologie des Quinze-Vints

Phone: +33 140021144

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Registry
ClinicalTrials.gov
Start date
3 July 2019
Est. completion
1 July 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Visualization of a structure of interest and measuring the short-term and long-term reproducibility of the data collected compared to routine systems

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov